Altimmune Inc (NASDAQ:ALT)
| 12.40 Delayed Data As of Sep 23 |  -0.95 / -7.12%Today’s Change | 3.83 Today|||52-Week Range 23.49 | +35.37% Year-to-Date |
Latest ALT News | Press Releases
| Altimmune's (ALT) Data From NASH Study Fail to Impress Investors Sep 15 / Zacks.com - Paid Partner Content |
Today’s Trading
| Previous close | 13.35 |
| Today’s open | 12.81 |
| Day’s range | 11.71 - 12.82 |
| Volume | 152,195 |
| Average volume (3 months) | 2,324,775 |
| Market cap | $706.5M |
Data as of 4:00pm ET, 09/23/2022
Growth & Valuation
| Earnings growth (last year) | -22.94% |
| Earnings growth (this year) | +16.17% |
| Earnings growth (next 5 years) | -- |
| Revenue growth (last year) | -46.12% |
| P/E ratio | NM |
| Price/Sales | 85.74 |
| Price/Book | 2.97 |
Competitors
| Today’s change | Today’s % change | |
|---|---|---|
| NSTGNanoString Technolog... | -0.12 | -0.91% |
| MORMorphoSys AG | -0.20 | -4.28% |
| AGENAgenus Inc | -0.10 | -4.46% |
| MRSNMersana Therapeutics... | -0.47 | -7.16% |
Data as of 4:00pm ET, 09/23/2022
Financials
| Next reporting date | November 15, 2022 |
| EPS forecast (this quarter) | -$0.51 |
| Annual revenue (last year) | $4.4M |
| Annual profit (last year) | -$97.1M |
| Net profit margin | -2,201.43% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Gaithersburg, Maryland |
Forecasts
